Schrödinger Management
Management criteria checks 4/4
Schrödinger's CEO is Ramy Farid, appointed in Jan 2008, has a tenure of 16.83 years. total yearly compensation is $3.12M, comprised of 21.7% salary and 78.3% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $3.49M. The average tenure of the management team and the board of directors is 7.1 years and 5.6 years respectively.
Key information
Ramy Farid
Chief executive officer
US$3.1m
Total compensation
| CEO salary percentage | 21.7% |
| CEO tenure | 16.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 7.1yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Schrödinger: Positive Signs Despite The Share Price Decline
Nov 21Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues Pushing Shares 26% Higher
Nov 13
Schrödinger's Path Forward: AI, Cash Burn, And Clinical Uncertainty
Oct 17Market Participants Recognise Schrödinger, Inc.'s (NASDAQ:SDGR) Revenues
Sep 27Schrodinger: More Drug Discovery Validation
Aug 06Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation
Aug 05We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right
Jun 12Schrödinger: More Pharmaceutical Than Software
May 07Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar
May 02Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially
Mar 01Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024
Mar 01Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Feb 28The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%
Feb 01Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable
Dec 18Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?
Sep 28Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?
Jul 01Schrödinger: Q2 Earnings Supports Growth Narrative
Aug 26Schrödinger appoints Dr. Geoffrey Porges as finance chief
Aug 18Sizing Up Schrodinger
Jun 06Schrödinger: Holding The Keys To Discovery
Mar 26Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too
Mar 15Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical
Jan 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$178m |
| Jun 30 2024 | n/a | n/a | -US$201m |
| Mar 31 2024 | n/a | n/a | -US$143m |
| Dec 31 2023 | US$3m | US$677k | US$41m |
| Sep 30 2023 | n/a | n/a | US$44m |
| Jun 30 2023 | n/a | n/a | US$66m |
| Mar 31 2023 | n/a | n/a | US$14m |
| Dec 31 2022 | US$4m | US$651k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$148m |
| Mar 31 2022 | n/a | n/a | -US$135m |
| Dec 31 2021 | US$8m | US$620k | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$81m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$9m | US$526k | -US$24m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$35m |
| Mar 31 2020 | n/a | n/a | -US$33m |
| Dec 31 2019 | US$633k | US$478k | -US$25m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$24m |
| Mar 31 2019 | n/a | n/a | -US$29m |
| Dec 31 2018 | US$1m | US$464k | -US$28m |
Compensation vs Market: Ramy's total compensation ($USD3.12M) is below average for companies of similar size in the US market ($USD5.38M).
Compensation vs Earnings: Ramy's compensation has been consistent with company performance over the past year.
CEO
Ramy Farid (59 yo)
16.8yrs
Tenure
US$3,124,165
Compensation
Dr. Ramy Farid, Ph.D. is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He serves as the President of Schrödinger, Inc. since January 2008 and has been its Chief Executive Officer since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 16.8yrs | US$3.12m | 0.25% $ 3.5m | |
| Co-Founder | 34.3yrs | US$1.09m | 1.69% $ 23.4m | |
| Executive VP & CFO | 2.3yrs | US$1.65m | 0.0078% $ 107.6k | |
| Executive VP | less than a year | US$1.70m | 0.0020% $ 27.0k | |
| President of Research & Development Therapeutics | 6.6yrs | US$1.68m | 0% $ 0 | |
| Chief Medical Officer | 1.3yrs | US$3.46m | 0.0031% $ 42.1k | |
| Co-Founder & Scientific Advisor | no data | no data | no data | |
| Executive VP | 7.6yrs | US$4.49m | 0.049% $ 680.2k | |
| Executive VP & Chief Information Officer | 7.8yrs | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Affairs | 4.8yrs | no data | no data | |
| Corporate Secretary | 14.8yrs | US$1.47m | 0.0086% $ 118.8k | |
| Senior Vice President of Materials Science | no data | no data | no data |
7.1yrs
Average Tenure
54.5yo
Average Age
Experienced Management: SDGR's management team is seasoned and experienced (7.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 11.9yrs | US$3.12m | 0.25% $ 3.5m | |
| Co-Founder | 34.3yrs | US$1.09m | 1.69% $ 23.4m | |
| Co-Founder & Scientific Advisor | no data | no data | no data | |
| Independent Chairman of the Board | 6.8yrs | US$727.05k | 0.0086% $ 118.3k | |
| Independent Director | 4.6yrs | US$689.55k | 0.0086% $ 118.3k | |
| Independent Director | 5.3yrs | US$707.05k | 0.0086% $ 118.3k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 5.8yrs | US$687.05k | 0.0086% $ 118.3k | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 5.2yrs | US$684.55k | 0.0086% $ 118.3k | |
| Independent Director | 4.6yrs | US$692.05k | 0.0086% $ 118.3k |
5.6yrs
Average Tenure
62yo
Average Age
Experienced Board: SDGR's board of directors are considered experienced (5.6 years average tenure).